Development of fusogenic liposomes which can deliver any substances into the cells through membrane fusion
开发融合脂质体,可通过膜融合将任何物质输送到细胞中
基本信息
- 批准号:07557312
- 负责人:
- 金额:$ 1.15万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:1995
- 资助国家:日本
- 起止时间:1995 至 1996
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Many investigators have examined liposomes as carriers for transporting substances into cells. However, conventional liposomes do not directly fuse with the cell membrane. Even when they are actively bound to the cell surface by adding an antibody or ligand on the surface, they are taken into the cell by endocytosis. Therefore, most substances encapsulated in liposomes are degraded by lysosome enzymes, resulting in loss of their efficiency. On the other hand, the envelope of the Sendai virus contains a protein responsible for binding and fusion to the cell membrane, and Sendai virus genes are introduced into cells via membrane fusion. Therefore, the introduced genes are not decomposed by lysomome enzymes. Based on these findings, fusogenic liposomes which possess the envelope proteins of the Sendai virus on the liposomal surface were developed. Fusogenic liposomes can introduce their encapsulated materials into the cytoplasm through direct membrane fusion. In this study, we examined th … More e preparation and characterization of unilamellar fusogenic liposome, and the efficiency of delivery of proteins and DNA by unilamellar fusogenic liposomes.A fusogenic liposome was generated by fusion between a Sendai virus particle and a simple liposome (PA : PC : CHOL=1 : 4 : 5 (mol)). The liposomes with a negative surface charge of phosphatidic acid (PA) gave the best results. The amount of cholesterol (30-50%) and the presence of sialic acid did not affect the efficiency of delivery. In addition, we purified fusogenic liposomes based on the difference of the density of the particles. The purified fusogenic liposomes are similar in size and structure to the Sendai virus particle, and fuse with cells as efficiently as the Sendai virus. These liposomes can fuse with cells derived from various species (human, monkey, rabbit, canine, cattle, mouse and hamster) and from various tissues (fibroblasts, epithelial cells, endothelial cells, hepatocytes, neuronal cells and lymphoma cells) with almost the same efficiency. They can deliver any substances that can be encapsulated in the liposomes, including genes or proteins, into the cells.In conclusion, the fusogenic lipsomes are new tools for direct introduction of genetic information into animal tissues. Less
许多研究者已经研究了脂质体作为将物质转运到细胞中的载体。然而,常规脂质体不直接与细胞膜融合。即使当它们通过在表面上添加抗体或配体而主动结合到细胞表面时,它们也通过内吞作用被摄入细胞。因此,大多数包封在脂质体中的物质被溶酶体酶降解,导致其效率损失。另一方面,仙台病毒的包膜含有负责与细胞膜结合和融合的蛋白质,仙台病毒基因通过膜融合被导入细胞。因此,引入的基因不被溶酶体酶分解。基于这些发现,开发了在脂质体表面上具有仙台病毒包膜蛋白的融合脂质体。融合脂质体可以通过直接膜融合将其包封的材料引入细胞质中。在这项研究中,我们检查了 ...更多信息 将仙台病毒颗粒与单脂质体(PA:PC:CHOL=1:4:5(mol))融合,制备了单层融合脂质体,并对融合脂质体的性质进行了研究。具有磷脂酸(PA)的负表面电荷的脂质体给出了最好的结果。胆固醇的量(30-50%)和唾液酸的存在不影响递送效率。此外,我们还根据融合脂质体颗粒密度的差异,对融合脂质体进行了纯化。纯化的融合脂质体在大小和结构上与仙台病毒颗粒相似,并且与仙台病毒一样有效地与细胞融合。这些脂质体可以与来自各种物种(人、猴、兔、犬、牛、小鼠和仓鼠)和来自各种组织(成纤维细胞、上皮细胞、内皮细胞、肝细胞、神经元细胞和淋巴瘤细胞)的细胞以几乎相同的效率融合。融合脂质体可以将任何可以包裹在脂质体中的物质(包括基因或蛋白质)导入细胞,是将遗传信息直接导入动物组织的新工具。少
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
中川哲彦、他: "遺伝子導入ベクターとしての膜融合リポソームの特性." Drug Delivery System. 11. 411-417 (1996)
Tetsuhiko Nakakawa 等人:“膜融合脂质体作为基因转移载体的特性。” 11. 411-417 (1996)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
T.Nakagawa, H.Mizuguchi, S.Imazu, M.Nakanishi, S.Nakagawa, T.Hayakawa, T.Mayumi: "Characterization of fusogenic liposomes as a gene transfer vector" Drug Delivery System. 11. 411-417 (1996)
T.Nakakawa、H.Mizuguchi、S.Imazu、M.Nakanishi、S.Nakakawa、T.Hayakawa、T.Mayumi:“融合脂质体作为基因转移载体的表征”药物输送系统。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAYUMI Tadanori其他文献
MAYUMI Tadanori的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAYUMI Tadanori', 18)}}的其他基金
Development of novel vaccine adjuvant for infectious disease
新型传染病疫苗佐剂的研制
- 批准号:
13557204 - 财政年份:2001
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of intracellular controlled release system for optimization of gene therapy
开发细胞内控释系统以优化基因治疗
- 批准号:
13470515 - 财政年份:2001
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Cancer gene therapy by the in vivo transfer of cytokine-genes in to the artery that leads to tumors with fusogenic liposomes.
癌症基因治疗通过将细胞因子基因体内转移到动脉中,用融合脂质体导致肿瘤。
- 批准号:
09557194 - 财政年份:1997
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Optimum bioconjugated cytokines selectively enhanced their therapeutic potency and reduces side-effects.
最佳的生物共轭细胞因子选择性地增强其治疗效力并减少副作用。
- 批准号:
09470512 - 财政年份:1997
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Preparation of aniti-tumor tissue endothelium antibodies and its application of cancer-missle therapy
抗肿瘤组织内皮抗体的制备及其在肿瘤导弹治疗中的应用
- 批准号:
07457615 - 财政年份:1995
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似国自然基金
Hm2E8-NCTD-liposomes靶向调节HLF/SLUG轴机制的研究
- 批准号:81200386
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes
多价 Tau 和 A-Beta 肽在免疫原性 SNAP 脂质体上的马赛克展示
- 批准号:
10699370 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Realization of blood-administered viral therapy using membrane-deformed liposomes
利用膜变形脂质体实现血液病毒治疗
- 批准号:
23K04927 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
STTR Phase I: Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury
STTR 第一期:用于治疗心肌再灌注损伤的强心阿托伐他汀脂质体
- 批准号:
2300933 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Standard Grant
Early Treatment With H12-(ADP)-liposomes Ameliorates Post-partum Hemorrhage With Coagulopathy Caused by Amniotic Fluid Embolism in Rabbits.
H12-(ADP)-脂质体的早期治疗可改善兔羊水栓塞引起的产后出血和凝血病。
- 批准号:
23K08828 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeted pan-antibacterial liposomes to control pathogenic mycobacteria
靶向泛抗菌脂质体控制致病性分枝杆菌
- 批准号:
10569282 - 财政年份:2023
- 资助金额:
$ 1.15万 - 项目类别:
Development of an in Vivo Assay for Liver Function Assessment Using Near-Infrared Fluorescent Liposomes
使用近红外荧光脂质体开发体内肝功能评估方法
- 批准号:
486369 - 财政年份:2022
- 资助金额:
$ 1.15万 - 项目类别:
Studentship Programs
Targeted delivery of antifungal drug loaded liposomes to control mucormycosis
靶向递送抗真菌药物脂质体来控制毛霉菌病
- 批准号:
10668509 - 财政年份:2022
- 资助金额:
$ 1.15万 - 项目类别:
Targeted delivery of antifungal drug loaded liposomes to control mucormycosis
靶向递送抗真菌药物脂质体来控制毛霉菌病
- 批准号:
10509943 - 财政年份:2022
- 资助金额:
$ 1.15万 - 项目类别:
Peptide conjugated liposomes activate anti-tumor immunity
肽缀合脂质体激活抗肿瘤免疫
- 批准号:
10371286 - 财政年份:2022
- 资助金额:
$ 1.15万 - 项目类别: